WO2025137648 - COMPOSITIONS AND METHODS FOR INNATE IMMUNE MODULATORS
National phase entry is expected:
Publication Number
WO/2025/137648
Publication Date
26.06.2025
International Application No.
PCT/US2024/061581
International Filing Date
20.12.2024
Title **
[English]
COMPOSITIONS AND METHODS FOR INNATE IMMUNE MODULATORS
[French]
COMPOSITIONS ET MÉTHODES POUR MODULATEURS IMMUNITAIRES INNÉS
Applicants **
ROSALIND THERAPEUTICS, INC.
Inventors
RADANY, Ernest William
Priority Data
63/612,941
20.12.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3222 | |
| EPO | Filing, Examination, Granting | 29099 | |
| Japan | Filing, Examination, Granting | 3173 | |
| South Korea | Filing, Examination, Granting | 4331 | |
| USA | Filing, Examination, Granting | 14710 |
Total:
54,535
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides compositions comprising a modified bactericidal permeability increasing protein (BPI) and pharmaceutical compositions thereof. The modified BPIs and pharmaceutical compositions thereof may be used in a variety of therapeutic methods for the treatment of immune related diseases or disorders.[French]
La présente divulgation concerne des compositions comprenant une protéine bactéricide augmentant la perméabilité bactéricide (BPI) et des compositions pharmaceutiques associées. Les BPI modifiées et les compositions pharmaceutiques de ceux-ci peuvent être utilisées dans une variété de méthodes thérapeutiques pour le traitement de maladies ou de troubles liés à l'immunité.